Cytokinetics
CYTK
276 hedge funds and large institutions have $4.88B invested in Cytokinetics in 2022 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 109 increasing their positions, 82 reducing their positions, and 35 closing their positions.
356% more call options, than puts
Call options by funds: $48.3M | Put options by funds: $10.6M
33% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 82
16% more capital inflows, than outflows
Capital inflows: $421M | Capital outflows: $364M
1.83% more ownership
Funds ownership: 111.11% → 112.93% (+1.8%)
0% more funds holding
Funds holding: 276 → 276 (0)
3% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 35
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$73.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$34M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$30.9M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$25.7M |
| 5 |
Eventide Asset Management
Boston,
Massachusetts
|
+$23.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Driehaus Capital Management
Chicago,
Illinois
|
-$53.4M |
| 2 |
Commodore Capital
New York
|
-$43.3M |
| 3 |
Deerfield Management
New York
|
-$39.4M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$35.9M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$22.1M |
CYTK Hedge Fund Activity: Q4 2022 in Review
276 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2022, worth a combined $4.88B — down 3.9% from $5.08B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of CYTK and 34 opened new positions — a net loss of 1 holder — while 82 trimmed existing stakes and 109 added.
The largest buyer was Wellington Management Group, adding an estimated $73.4M. The largest seller was Driehaus Capital Management, cutting an estimated $53.4M.
- 276 institutional investors held Cytokinetics (CYTK) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $4.88B of Cytokinetics stock for Q4 2022, down 3.9% quarter-over-quarter.
- 34 funds opened new Cytokinetics positions in Q4 2022 and 35 closed out, a net change of -1 holder.
- The largest Cytokinetics buyer in Q4 2022 was Wellington Management Group, an estimated $73.4M added.
- The largest Cytokinetics seller in Q4 2022 was Driehaus Capital Management, an estimated $53.4M sold.
Based on aggregated 13F filings for Q4 2022.